iCAD, Inc. (NASDAQ: ICAD) shares kicked off Wednesday flat. The Nashua, New Hampshire-based company, claiming to be a global leader “on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions,” today announced that five clinical presentations and abstracts highlighting the Company’s advancements in breast cancer detection, risk evaluation, and breast arterial calcification (BAC) assessment have been accepted for presentation at the European Congress of Radiology (ECR) 2025, which will take place from February 26 to March 2, in Vienna, Austria.
Led by research collaborators, these studies underscore iCAD’s commitment to delivering artificial intelligence (AI) powered solutions to advance personalized risk assessment, enhance early detection, and optimize breast imaging workflows.
“At iCAD, we are committed to pushing the boundaries of AI innovation in breast health, and the research being presented at ECR 2025 underscores the real-world impact and potential of our solutions,” said iCAD CEO Dana Brown, “These studies highlight how our solutions are advancing personalized risk evaluation, improving early detection, optimizing breast imaging workflows, and expanding the application of AI insights from a mammograph beyond breast health, ultimately supporting better outcomes for patients and providers worldwide. In line with this commitment, iCAD will present the new ProFound Cloud, a secure, scalable SaaS platform designed to deliver the company’s advanced AI solutions to healthcare providers worldwide.”
ICAD shares were static Wednesday at $2.93.
